approval · primary record
AMIVANTAMAB AND HYALURONIDASE-LPUJ
FDA · BLA · 2026-02-13
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Action date | 2026-02-13 |
| Brand | RYBREVANT FASPRO |
| Sponsor | JANSSEN BIOTECH |
| Route | SINGLE-USE |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-28T10:41:02.415Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: FDA:AMIVANTAMAB AND HYALURONIDASE-LPUJ:2026-02-13
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab And Hyaluronidase-Lpuj · compound